US Delays Review of First Nonprescription Birth-Control Pill (1)

The US Food and Drug Administration delayed a meeting to review whether Perrigo Co.’s birth-control product Opill can be sold without a prescription.

A scheduled Nov. 18 meeting of outside experts to advise the agency has been put off and no new date was given, the generic-drug maker said Wednesday. The agency wants to study additional information about the product.

If approved, Opill would become the first daily, over-the-counter oral contraceptive in the US. Perrigo’s HRA Pharma sought FDA approval in July, after the Supreme Court overturned the landmark decision Roe v. Wade, the near 50-year-old ruling legalizing abortion ...